Janone encouraged by recent fda communications regarding phase 2b clinical trial design of lead drug candidate jan101

Las vegas, sept. 28, 2021 /prnewswire/ -- janone inc. (nasdaq: jan), a company that focuses on the development of treatments for conditions that cause severe pain – in conjunction with its continuing focus on the development of drugs with non-addictive, pain-relieving properties – today announced that it is revising its development strategy based on recent communications with the u.s. food and drug administration (fda) for its upcoming clinical trial of lead drug candidate jan101 as a treatment for peripheral artery disease (pad).
JAN Ratings Summary
JAN Quant Ranking